Johan Sebregts

Director/Board Member at River Biomedics B V I.O.

Finance

Health Technology

Profile

Johan Sebregts has worked as a Director at Segestio BV since 2012 and currently holds a position as a Non-Executive Director at River Biomedics B V I.O.

Johan Sebregts active positions

Companies	Position	Start
Segestio BV Segestio BV Investment ManagersFinance Segestio BV is an independent private equity firm with its headquarters in Vlissingen, the Netherlands. It was founded in 2012.	Private Equity Investor	2012-09-30
River Biomedics B V I.O. River Biomedics B V I.O. Medical SpecialtiesHealth Technology River Biomedics B V I.O. is a Dutch biotech company that focuses on cardiac drug discovery. The company is based in Enschede, Netherlands. The company develops novel therapies for cardiac diseases by directly targeting the heart muscle using human predictive 3D in-vitro models and human induced pluripotent stem cell (hiPSC) technology. The company aims to address high unmet medical needs and provide detailed clinically relevant read-outs through high-throughput in-house screening platforms. River Biomedics values partnerships and strives for novelty by mimicking nature and connecting biology and engineering. The company was founded by Marcelo Ribeiro, Robert Passier, Lisanne Blauw, and the CEO is Nicky Cooper.	Director/Board Member	-

All active positions of Johan Sebregts

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Johan Sebregts's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Segestio BV Segestio BV Investment ManagersFinance Segestio BV is an independent private equity firm with its headquarters in Vlissingen, the Netherlands. It was founded in 2012.	Finance
River Biomedics B V I.O. River Biomedics B V I.O. Medical SpecialtiesHealth Technology River Biomedics B V I.O. is a Dutch biotech company that focuses on cardiac drug discovery. The company is based in Enschede, Netherlands. The company develops novel therapies for cardiac diseases by directly targeting the heart muscle using human predictive 3D in-vitro models and human induced pluripotent stem cell (hiPSC) technology. The company aims to address high unmet medical needs and provide detailed clinically relevant read-outs through high-throughput in-house screening platforms. River Biomedics values partnerships and strives for novelty by mimicking nature and connecting biology and engineering. The company was founded by Marcelo Ribeiro, Robert Passier, Lisanne Blauw, and the CEO is Nicky Cooper.	Health Technology